[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Biogen's Turnaround Thesis Hangs on Whether New Products Can Offset the MS Decline

Biogen Inc. (BIIB) reports first-quarter 2026 earnings before the market opens on Tuesday, April 29th, with Wall Street bracing for a year-over-year decline in profitability despite the company's recent string of earnings beats. The central question: can management's Alzheimer's franchise momentum and pipeline progress offset near-term revenue headwinds from multiple sclerosis competition and patent pressures? With analyst sentiment improving and the stock trading near $183, the biotech's ability to deliver on its late-stage pipeline while navigating a challenging commercial landscape will determine whether recent gains hold or reverse.

Biogen is a global biotechnology company focused on developing therapies for neurological, neurodegenerative, and...

Fundamentals

See More
  • Market Capitalization, $K 28,527,016
  • Shares Outstanding, K 146,759
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,377 M
  • EBITDA $ 3,451 M
  • 60-Month Beta 0.16
  • Price/Sales 2.72
  • Price/Cash Flow 7.98
  • Price/Book 1.45

Options Overview Details

View History
  • Implied Volatility 36.59% (-1.75%)
  • Historical Volatility 35.82%
  • IV Percentile 62%
  • IV Rank 38.81%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 1) 4.87 (2.51%)
  • Put/Call Vol Ratio 2.26
  • Today's Volume 7,568
  • Volume Avg (30-Day) 2,112
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 53,947
  • Open Int (30-Day) 48,931
  • Expected Range 189.51 to 199.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $4.18
  • Number of Estimates 25
  • High Estimate $4.80
  • Low Estimate $3.20
  • Prior Year $5.47
  • Growth Rate Est. (year over year) -23.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
168.64 +15.26%
on 04/06/26
195.89 -0.77%
on 04/29/26
+10.54 (+5.73%)
since 03/27/26
3-Month
168.64 +15.26%
on 04/06/26
202.41 -3.97%
on 02/06/26
+18.20 (+10.33%)
since 01/29/26
52-Week
115.25 +68.66%
on 05/08/25
202.41 -3.97%
on 02/06/26
+74.21 (+61.75%)
since 04/29/25

Most Recent Stories

More News
Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 Sales

Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 Sales

BIIB : 194.38 (+6.00%)
Biogen's Turnaround Thesis Hangs on Whether New Products Can Offset the MS Decline

Barchart Research What to Expect from BIIB Earnings BIIB Generated April 28, 2026 Current Price $183.38 EPS Estimate $$2.96 Consensus Rating Moderate Buy Average Move 2.80% Biogen's Turnaround Thesis Hangs...

BIIB : 194.38 (+6.00%)
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

BIIB : 194.38 (+6.00%)
3 Profitable Stocks We Steer Clear Of

3 Profitable Stocks We Steer Clear Of

NOC : 572.41 (-0.94%)
BYD : 86.29 (-0.66%)
BIIB : 194.38 (+6.00%)
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen

Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen

LCID : 5.76 (-1.87%)
ULTA : 530.23 (-1.47%)
FROG : 46.27 (+1.69%)
CDNS : 329.95 (+1.43%)
BIIB : 194.38 (+6.00%)
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

BIIB : 194.38 (+6.00%)
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals...

APLS : 40.95 (-0.10%)
BIIB : 194.38 (+6.00%)
Biogen (BIIB) Stock Trades Up, Here Is Why

Biogen (BIIB) Stock Trades Up, Here Is Why

BIIB : 194.38 (+6.00%)
Biogen Earnings Preview: What to Expect

Biogen is poised to announce its first-quarter results next week, and analysts predict a marginal drop in the company’s bottom-line figure.

XLV : 142.84 (-0.70%)
$SPX : 7,135.95 (-0.04%)
BIIB : 194.38 (+6.00%)
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed...

BIIB : 194.38 (+6.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 215.83
2nd Resistance Point 205.86
1st Resistance Point 200.12
Last Price 194.38
1st Support Level 184.41
2nd Support Level 174.44
3rd Support Level 168.70

See More

52-Week High 202.41
Last Price 194.38
Fibonacci 61.8% 169.11
Fibonacci 50% 158.83
Fibonacci 38.2% 148.55
52-Week Low 115.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.